Cefazolin Sandoz

Riik: Uus-Meremaa

keel: inglise

Allikas: Medsafe (Medicines Safety Authority)

Toimeaine:

Cefazolin sodium 1048mg equivalent to cefazolin 1 g

Saadav alates:

Novartis New Zealand Ltd

INN (Rahvusvaheline Nimetus):

Cefazolin sodium 1048 mg (=cefazolin 1 g)

Annus:

1 g

Ravimvorm:

Powder for injection

Koostis:

Active: Cefazolin sodium 1048mg equivalent to cefazolin 1 g

Ühikuid pakis:

Vial, glass, 1 x 1 g vial, 1 g

Klass:

Prescription

Retsepti tüüp:

Prescription

Valmistatud:

Sandoz GmbH

Toote kokkuvõte:

Package - Contents - Shelf Life: Vial, glass, 1 x 1 g vial - 1 g - 36 months from date of manufacture stored at or below 25°C 24 hours reconstituted stored at 2° to 8°C (Refrigerate, do not freeze) - Vial, glass, 5 x 1 g vials - 5 g - 36 months from date of manufacture stored at or below 25°C 24 hours reconstituted stored at 2° to 8°C (Refrigerate, do not freeze) - Vial, glass, 10 x 1 g vials - 10 g - 36 months from date of manufacture stored at or below 25°C 24 hours reconstituted stored at 2° to 8°C (Refrigerate, do not freeze)

Loa andmise kuupäev:

2005-11-10

Toote omadused

CEFAZOLIN SANDOZ 
_CEFAZOLIN SODIUM PH EUR, POWDER FOR INJECTION, 500 MG AND 1 G
(AS CEFAZOLIN) _
PRESENTATION 
Cefazolin Sandoz is a white to slightly yellowish powder
aseptically filled into glass vials. 
Cefazolin Sandoz 500 mg contains in a 15 ml vial, sterile cefazolin sodium equivalent to cefazolin 500 mg. 
Cefazolin Sandoz 1 g contains in
a 15 ml vial, sterile cefazolin sodium equivalent to
cefazolin 1 g. 
USES 
_ACTIONS _
PHARMACOTHERAPEUTIC GROUP 
J01DA04 
– Cephalosporins and related substances, cefazolin. 
MECHANISM OF ACTION 
Beta-lactam antibiotic. 
PHARMACODYNAMIC EFFECTS 
Inhibition of bacterial cell wall synthesis. 
ANTIBIOTIC CLASS 
Semi-synthetic cephalosporin for intramuscular
or intravenous administration. 
ANTIBIOTIC NATURE AND MODE OF ACTION 
_In vitro _tests demonstrate that
the bactericidal action of cephalosporins results from inhibition
of cell-
wall synthesis. 
SUSCEPTIBILITY DATA 
Cefazolin is active against the following organisms _in
vitro _and in clinical infections: _Staphylococcus _
_aureus_ (including
penicillinase-producing strains); _Staphylococcus epidermidis; _group A beta-
haemolytic streptococci and other
strains of streptococci (many strains of enterococci are
resistant); 
_Streptococcus pneumoniae; Escherichia
coli; Klebsiella _sp.; _Proteus mirabilis; Haemophilus _
_influenzae; Enterobacter aerogenes._ 
Quantitative methods that require measurement of zone
diameters give the most precise estimates of 
antibiotic susceptibility. One such procedure has been recommended
for use with discs for testing 
susceptibility to cefazolin. With this procedure, a report
from the laboratory of "susceptible" indicates 
that the infecting organism is likely to respond to
therapy. A report of "resistant" indicates that the 
infecting organism is not likely to respond to
therapy. A report of "moderately